Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | UTS2R | Q9UKP6 | 3/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5465439 | 0.93 | DRD2 (0.36) | DRD2MAPTKDM4EKMT2ANPSR1 | |
| SCHEMBL5474586 | 0.92 | PARP1 (0.40) | DRD2MAPTKDM4EKMT2ANPSR1 | |
| SCHEMBL5853907 | 0.91 | PARP1 (0.40) | DRD2MAPTKDM4EKMT2ANPSR1 | |
| SCHEMBL6304809 | 0.87 | MAPT (0.39) | DRD2MAPTKDM4EKMT2ANPSR1 | |
| SCHEMBL5473212 | 0.86 | MAPT (0.40) | MAPTKDM4EKMT2ANPSR1TDP1 | |
| SCHEMBL5472786 | 0.85 | MAPT (0.41) | MAPTKDM4EKMT2ANPSR1TDP1 | |
| SCHEMBL5467225 | 0.85 | MAPT (0.39) | MAPTKDM4EKMT2ANPSR1TDP1 | |
| SCHEMBL5464742 | 0.84 | MAPT (0.42) | MAPTKDM4EKMT2ANPSR1PARP1 | |
| SCHEMBL7092472 | 0.83 | HSD17B10 (0.37) | DRD2MAPTKMT2ANPSR1HSD17B10 | |
| SCHEMBL5464875 | 0.83 | MAPT (0.34) | MAPTKDM4EKMT2ANPSR1RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070049583-A1 | Benzoxazine and benzothiazine derivatives and their use in pharmaceutical agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-03-01 | — | — | US | disclosed |
| US-7141566-B1 | Benzoxazine and benzothiazine derivatives and the use thereof in medicaments | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049583-A1 | Benzoxazine and benzothiazine derivatives and their use in pharmaceutical agents | CYP3A5, XDH, CYP4Z1 | DRD2 2978/4885MAPT 10/4885KDM4E 3444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.